RESUMO
Se efectúa una breve revisión del tratamiento del ectima gangrenoso. El ceftazimide demostró menor morbi-mortalidad, mientras que los amino glucósidos y el imipemen, mayor mortalidad y resistencia respectivamente.
A brief review about the best treatment of the echthyma gangrenosum are reported. Ceftazidime showed less morbi-mortality while aminoglycosides and imipenem higher mortality and resistance.
RESUMO
El Síndrome de Peutz Jeghers (SPJ) es una enfermedad genética poco frecuente, que se caracteriza por máculas pigmentadas en piel y mucosas, asociado a pólipos hamartomatosos en el tracto digestivo, junto a un aumento en el riesgo del desarrollo tanto de cáncer gastrointestinal, como no gastrointestinal. El 70% de los casos de SPJ, se manifiesta como una condición hereditaria autosómica dominante, mientras que el 30% restante es el resultado de mutaciones espontáneas. El principal gen responsable es STK11/LKB1. Esta revisión actualizada aborda los principales aspectos clínicos y genéticos del síndrome.
Peutz Jeghers Syndrome (PJS) is a rare genetic disorder characterized by macular lesions on the skin and mucous membranes together with hamartomatous polyps in the gastrointestinal tract, with and increased risk of developing both gastrointestinal and non gastrointestinal neoplasms. Seventy percent of cases of SPJ manifest as an autosomal dominant inherited condition, whereas the remaining 30% are the result of spontaneous mutations. The STK11/LKB1 gene is the main cause of this disorder. The purpose of this updated review is to show the newest clinical and genetic aspects.
RESUMO
Calcinosis cutis is a chronic calcium-mediated disease that causes significant morbidity. Multiple treatments have been tried, with varying results; indeed, to date, no standard treatment has been generally accepted. Sodium metabisulfite is an inorganic compound that, when it reacts with oxygen, becomes sodium sulfate, a metabolite of sodium thiosulfate that has a similar ability to inhibit calcium oxalate agglomeration. Four women diagnosed with calcinosis cutis, secondary to dermatomyositis, systemic sclerosis and radiodermatitis after breast cancer, were evaluated for their response to topical 25% sodium metabisulfite. In all patients a decrease in lesion size, erythema and pain from injuries was shown, with complete resolution of the associated ulcers. One patient had a complete response. None experienced adverse effects. Topical sodium metabisulfite is a promising emerging therapy that should be considered as a valid alternative treatment in calcinosis cutis. Randomized prospective studies are required to evaluate its true efficacy.